Breast cancer patients ‘denied life-extending drugs because of unfair system’

Thousands of women with advanced breast cancer could be denied life-extending drugs because of the “unfair” way they are assessed for use on the health service, a charity has warned. Breast Cancer Now ... Read More

AstraZeneca's Enhertu breast cancer drug added to China's state insurance list | Reuters

AstraZeneca's blockbuster breast cancer drug Enhertu will be added to China's state-run health insurance scheme from Jan. 1, according to an update from the National Healthcare Security ... Read More

This Supreme Court Health Insurance Ruling Affects 150 Million Americans—What This Means for Cancer Patients

In a critical victory for patients on June 27th, the Supreme Court has determined that health insurance plans under the Affordable Care Act (ACA), also known as Obamacare, must continue to fully cover ... Read More

AstraZeneca cancer drug Enhertu added for reimbursement in China despite probe - MSN

The drugs selected for this year's list are expected to fall by an average of 63%. China is AstraZeneca's ( AZN ) third-biggest market, adding as much as $5.8B in revenue for the company in 2023. Read More

Daiichi and AstraZeneca’s Enhertu shows PFS benefits in breast cancer trial - Yahoo Finance

Daiichi Sankyo and AstraZeneca's Enhertu (trastuzumab deruxtecan) with pertuzumab has shown progression-free survival (PFS) improvement in the Phase III DESTINY-Breast09 trial, when used as a ... Read More

AstraZeneca (AZN) Sees Its Cancer Drug Added to China’s Reimbursement List | Nasdaq

Drugmakers AstraZeneca (AZN) and Daiichi Sankyo’s (DSKYF) cancer drug, Enhertu, has been added to China’s National Reimbursement Drug List (NRDL) and will be covered by state-run medical ... Read More

AstraZeneca & Daiichi Sankyo’s Enhertu Posts Positive Data as First-Line Breast Cancer Therapy - MedCity News

Enhertu is currently approved as a second-line treatment for HER2-positive metastatic breast cancer. The new results for the AstraZeneca and Daiichi Sankyo drug in the first-line setting are ... Read More

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO - NBC Los Angeles

A Merck, Daiichi Sankyo drug disappoints in lung cancer – Merck and Daiichi Sankyo on Thursday said they have withdrawn their U.S. application for an experimental treatment after it failed to ... Read More

EU backs AstraZeneca, Daiichi's Enhertu for breast cancer treatment post endocrine therapy | Reuters

Feb 28 (Reuters) - The European Union's health regulator on Friday backed AstraZeneca (AZN.L), opens new tab and Daiichi Sankyo's (4568.T), opens new tab drug Enhertu as a breast cancer treatment ... Read More

European Drug Regulator Approves AstraZeneca's Two Flagship Cancer Drugs For Breast And Lung Cancer Settings - AstraZeneca (NASDAQ:AZN) - Benzinga

The European Commission on Friday approved AstraZeneca Plc AZN and Daiichi Sankyo's DSKNY Enhertu (trastuzumab deruxtecan) as a monotherapy for a type of breast cancer.. The approval covers adult ... Read More

NHS watchdog blocks AstraZeneca breast cancer drug - Financial Times

England’s healthcare spending watchdog has blocked the NHS from providing an innovative treatment for a form of advanced breast cancer, blaming AstraZeneca and Japanese company Daiichi Sankyo ... Read More

AstraZeneca's Enhertu breast cancer drug added to China's state insurance list - Yahoo Finance

SHANGHAI (Reuters) -AstraZeneca's blockbuster breast cancer drug Enhertu will be added to China's state-run health insurance scheme from Jan. 1, according to an update from the National Healthcare ... Read More